||EPS - Basic
||Market Cap (m)
|Pharmaceuticals & Biotechnology
Amryt Pharma Share Discussion Threads
Showing 876 to 900 of 900 messages
|I would hope that the operational costs will be covered in part (eventually in full) by our recent alliance.
They are also accountable to the EIB following their new €20M credit line so won't be able line their pockets at our expense.|
|Nearly a year in operation and all it does is go down. The directors gravy train keeps chugging along. Admin costs are horrendous here given the contempt the directors hold shareholders in.|
|I'm NOT worried about the lack of investor interest, pottermagic, just commenting on it, that's all. Where in my post does it say that I'm worried?|
|The prospects are definately good. By now they should be asking questions of their PR firm. The message is clearly not getting to those that need to know!
We should not be merely waiting for someone to take notice!|
|Why worry about Investor interest at such a low level.
It's a Business that simply needs to generate Products and/or make good, reported progress with its development of Products.
The Market valuation will thrive on actual progress with Products.
A bigger Fish may show considerable interest, to the benefit of the Market valuation, based on good progress.
All we can do is sit & wait|
|Another day of very low volume. Currently investors are not interested in AMYT. We await the next news; only that will rekindle investor interest.|
|Looking more and more likely that the chart watchers are going to be proved correct and that the GAP UP between 16.5 - 18p that occurred on the candlestick chart following the good news issued in early December will need to be FILLED before further upwards progress can seen in the share price We shall see!|
|Understood Pottermagic - so the market may not be established, product less saleable, fewer instances of the ailment (not sure about that last one), but if we sell half as much despite having twice (or maybe 3 times) the number of people....
That will do me!|
|I expect it's about Demand and affordability... we've been given Markets that the Product is perhaps less attractive to, maybe less affordable, possibly fewer instances of the ailment itself occurring ?
Novelion wasn't going to give us it's Primary Market where it already makes plenty of Sales and a sizeable Profit... it's given us a very secondary target Market where it hasn't made much traction itself.|
|According to Novelion's 'preliminary total net product sales for 2016', the company anticipates $100 Million from Juxtapid (lomitapide). We have been licenced exclusively to sell the hard capsule version (Lojuxta) in the EEA, Middle East and North Africa. 70% of Novelion's sales appear to be in the US.
Assuming that the territories we now control have over twice the population of the US, why are we languishing at £38M market cap. What am I missing here?|
|Looking like the chart followers could be proved correct on this one and that the GAP UP on the candlestick chart between 16.5 - 18p that happened early in December will be filled. We shall see. What will be will be. If the share price does fall back below 17p it could be a good time to top up.|
|Many thanks, Buffy.|
Just one of several explanations.
Agreed a bit confusing.
Some may say that all biopharmas are biotechs, but not all biotechs are biopharmas.
I won't care when the company finally hits it big.
|Here's my post from around a month ago.
papillon 15 Dec '16 - 12:23 - 714 of 774 1 0 Edit
Looks like the AMYT share price could have run out of steam in the short term. There is an intraday "GAP" on the AMYT candlestick chart from earlier this month following the release of good news. That "GAP" is between 16.5p and 18p. Chartists (of which I'm not one though I don't completely ignore them like some) would argue that that "GAP" needs to be filled. If those chartists are correct then the AMYT share price will drop back to 16.5p intraday before further upward progress can take place. We shall see. I can't predict the future and I'm not interested in short term share price fluctuations since rightly, or wrongly, I believe that holding AMYT for the longer term will make me an exceedingly good profit. My AMYT shares will stay in my bottom drawer. I await the next news with anticipation.|
|GAP UP between 16.5 - 18.0 pence that occurred in early December about to be CLOSED? Looking possible! Gap ups are often "closed" by a drop back in the share price before the climb back up restarts. We shall see!
PS. I first mentioned that this Gap up might need to be closed a month, or so, ago, but it doesn't always happen. Is it happening now because traders are closing positions?|
|I knew as I was writing it that it was a daft comment ....|
|Oh well. Just when you thought... :-/|
|Lots of sells but at least the price is holding (so far). Let's hope once these sells are finished we can start to climb!|
|Its only a matter of time and patience|
|I agree with you, bigdavewave. The AMYT share price is drifting sideways probably awaiting the next RNS and this USA conference will not provide the necessary fireworks to propel the share price upwards; only a good RNS from the company will do that, IMO. Fingers crossed!|
|buffy, what's the difference between a biopharma company and a biotech company? I would suggest that AMYT could be decscribed as both.|
|By the way, I wouldn't expect any fireworks to come out this conf. I doubt it works that way. Maybe some quiet investor chats, presentations etc. No idea, frankly. But it is all added exposure which is good.|
Are we not a biopharma company anymore?
|The link you have shown, pottermagic2310, is for JP Morgan's EUROPEAN healthcare conference whereas the one bigdavewave is talking about is the JP Morgan NORTH AMERICAN healthcare conference. BIG DIFFERENCE. Please pay more attention to what bigwavedave posts, pottermagic! LOL.
I would suggest that the North American conference is the more important one since biotech is much bigger in the USA than Europe.|
|Really? Who did the VP think he was talking to then? haha